ABBV - Comparative Study: AbbVie And Industry Competitors In Biotechnology Industry | Benzinga
In today's fast-paced and highly competitive business world, it is crucial for investors and industry followers to conduct comprehensive company evaluations. In this article, we will delve into an extensive industry comparison, evaluating AbbVie (NYSE:ABBV) in relation to its major competitors in the Biotechnology industry. By closely examining key financial metrics, market standing, and growth prospects, our objective is to provide valuable insights and highlight company's performance in the industry.
AbbVie Background
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
| Company | P/E | P/B | P/S | ROE | EBITDA (in billions) | Gross Profit (in billions) | Revenue Growth |
|---|---|---|---|---|---|---|---|
| AbbVie Inc | |||||||
| 50.73 | |||||||
| 37.59 | |||||||
| 5.55 | |||||||
| 14.8% | |||||||
| $4.49 | |||||||
| $8.22 | |||||||
| 0.7% | |||||||
| Amgen Inc | |||||||
| 43.53 | |||||||
| 32.55 | |||||||
| 5.55 | |||||||
| -2.01% | |||||||
| $2.15 | |||||||
| $4.25 | |||||||
| 21.98% | |||||||
| Vertex Pharmaceuticals Inc | |||||||
| 31.37 | |||||||
| 6.73 | |||||||
| 12.37 | |||||||
| 6.09% | |||||||
| $1.34 | |||||||
| $2.35 | |||||||
| 13.3% | |||||||
| Regeneron Pharmaceuticals Inc | |||||||
| 29.60 | |||||||
| 4.09 | |||||||
| 8.72 | |||||||
| 2.73% | |||||||
| $0.83 | |||||||
| $2.71 | |||||||
| -0.54% | |||||||
| Gilead Sciences Inc | |||||||
| 181.25 | |||||||
| 4.63 | |||||||
| 2.98 | |||||||
| -20.66% | |||||||
| $-3.54 | |||||||
| $5.13 | |||||||
| 5.26% | |||||||
| Biogen Inc | |||||||
| 28.25 | |||||||
| 2.16 | |||||||
| 3.41 | |||||||
| 2.62% | |||||||
| $0.68 | |||||||
| $1.75 | |||||||
| -7.0% | |||||||
| BioNTech SE | |||||||
| 192.94 | |||||||
| 1.09 | |||||||
| 8.03 | |||||||
| -1.57% | |||||||
| $-0.29 | |||||||
| $0.13 | |||||||
| -85.31% | |||||||
| Genmab A/S | |||||||
| 23.04 | |||||||
| 3.78 | |||||||
| 7.08 | |||||||
| 4.13% | |||||||
| $1.72 | |||||||
| $3.96 | |||||||
| 46.19% | |||||||
| Biomarin Pharmaceutical Inc | |||||||
| 78.25 | |||||||
| 3.10 | |||||||
| 6.47 | |||||||
| 1.77% | |||||||
| $0.14 | |||||||
| $0.52 | |||||||
| 8.79% | |||||||
| Neurocrine Biosciences Inc | |||||||
| 36.63 | |||||||
| 5.69 | |||||||
| 6.98 | |||||||
| 1.88% | |||||||
| $0.04 | |||||||
| $0.51 | |||||||
| 22.57% | |||||||
| Incyte Corp | |||||||
| 18 | |||||||
| 2.48 | |||||||
| 3.57 | |||||||
| 3.2% | |||||||
| $0.26 | |||||||
| $0.82 | |||||||
| 8.93% | |||||||
| United Therapeutics Corp | |||||||
| 13.03 | |||||||
| 2.29 | |||||||
| 5.48 | |||||||
| 5.42% | |||||||
| $0.43 | |||||||
| $0.6 | |||||||
| 33.7% | |||||||
| Sarepta Therapeutics Inc | |||||||
| 285.33 | |||||||
| 12.07 | |||||||
| 8.32 | |||||||
| 3.97% | |||||||
| $0.05 | |||||||
| $0.36 | |||||||
| 63.1% | |||||||
| Roivant Sciences Ltd | |||||||
| 2.02 | |||||||
| 1.31 | |||||||
| 70.46 | |||||||
| -2.51% | |||||||
| $-0.18 | |||||||
| $0.02 | |||||||
| 5.68% | |||||||
| Average | |||||||
| 74.1 | |||||||
| 6.31 | |||||||
| 11.49 | |||||||
| 0.39% | |||||||
| $0.28 | |||||||
| $1.78 | |||||||
| 10.51% |